Despite the remarkable efficacy of PI3K inhibitors combined with fulvestrant in advanced breast cancer, the incidence of grade ≥3 adverse events was significantly higher in patients receiving PI3K inhibitors combined with fulvestrant (RR = 2.11), with high heterogeneity observed (I2 = 58%). Here, PIK3CA is linked to breast carcinoma.